Omnicell Inc. has announced its financial results for the first quarter of 2025, reporting an increase in total revenues to $270 million, up by $24 million or 10% compared to the first quarter of 2024. This growth is attributed to higher revenues from the XT Amplify program and continued expansion in SaaS and Expert Services, with a notable contribution from Specialty Pharmacy Services. The company's GAAP net loss for the first quarter was $7 million, or $0.15 per diluted share, an improvement from a GAAP net loss of $16 million, or $0.34 per diluted share, in the same period of 2024. On a non-GAAP basis, Omnicell reported a net income of $12 million or $0.26 per diluted share, compared to $1 million or $0.03 per diluted share in the first quarter of the prior year. Non-GAAP EBITDA also showed significant improvement, reaching $24 million, up from $11 million in the first quarter of 2024. Omnicell highlighted its focus on driving annual recurring revenue services and mitigating the potential impact of tariffs on its supply chain. The company maintains a strong balance sheet and solid free cash flow, positioning it well to navigate the current macroeconomic environment and continue delivering innovative solutions to its customers.